Author/Authors :
LARIJANI, BAGHER tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , TABATABAEI, OZRA tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , SOLTANI, AKBAR tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , TAHERI, EGHBAL tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , PAJOUHI, MOHAMMAD tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , BASTANHAGH, MOHAMMAD-HASSAN tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , AKHONDZADEH, SHAHIN tehran university of medical sciences tums - Institute of Medical Plants - RoozbehPsychiatric Hospital, تهران, ايران , MAHMOODI, MAHMOOD tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , BANDARIAN, FATHEMEH tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران , MOHAMMADZADE, NOSRATOLLAH tehran university of medical sciences tums - Endocrinology and Metabolism Research Center, تهران, ايران
Abstract :
Desmoperssin is the drug of choice for treatment of central diabetes insipidus and most commonly it isused as intranasal spray. In this study, efficacy and side effects of oral desmopressin was compared withthe intranasal spray. This study was before -after clinical trial on 14 outpatients (9 F, 5 M, age 14 -50 Y)with central diabetes insipidus who had been treated with intranasal spray of desmopressin previously.Weight, pulse rate and blood pressure (sitting -standing), biochemical profile, serum electrolytes, 24hurine volume, specific gravity of urine and LFT was measured before and after 1 month study. Startingdose for each patient was one oral tablet of DDAVP (0.1 mg) per 8 hours. Paired Samples T-Test wasused for data analysis. No clinically significant changes were found as regard to weight, pulse rate, bloodpressure, blood chemistry, electrolyte and urinalysis. Single reported adverse effect was headache (43%)in tablet group and dyspnea (7%) in spray group. Both dosage forms were able to control diurnal polyuriaand nocturnal polyuria. The antidiuretic dose - equivalence ratio for intranasal to oral desmopressin was1: 18. Spray was superior in terms of rapid onset of action and duration of antidiuretic action in 100% and78% of cases (not significant), respectively. Tablets were more available and much more easily consumedas reported by patients, in 86% (P=0.0006). Treatment with tablets offers a good alternative to theintranasal route, especially in patients with chronic rhinitis or common cold and similar conditions.
